

1. Record Nr.	UNINA9910880299903321
Autore	Berger Stephen
Titolo	COVID-19
Pubbl/distr/stampa	Los Angeles : , : Gideon Informatics, Incorporated, , 2024 ©2024
ISBN	1-4988-4241-0
Edizione	[2024th ed.]
Descrizione fisica	1 online resource (1175 pages)
Altri autori (Persone)	GIDEON science teamGideon science
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di contenuto	Intro -- Copyright -- Introduction: The GIDEON e-book series -- Table of Contents -- COVID-19 -- Epidemiology -- Agent -- Reservoir -- Vector -- Vehicle -- Incubation Period -- Diagnostic Tests -- Typical Adult Therapy -- Typical Pediatric Therapy -- Vaccines -- Clinical Hints -- Synonyms -- References -- Clinical -- References -- Distribution Map -- Images -- Global status -- References -- Afghanistan -- References -- Albania -- References -- Algeria -- References -- American Samoa -- References -- Andorra -- References -- Angola -- References -- Anguilla -- References -- Antigua and Barbuda -- References -- The Antilles (miscellaneous) -- References -- Argentina -- References -- Armenia -- References -- Aruba -- References -- Australia -- References -- Austria -- References -- Azerbaijan -- References -- The Azores -- References -- The Bahamas -- References -- Bahrain -- References -- Bangladesh -- References -- Barbados -- References -- Belarus -- References -- Belgium -- References -- Belize -- References -- Benin -- References -- Bermuda -- References -- Bhutan -- References -- Bolivia -- References -- Bosnia and Herzegovina -- References -- Botswana -- References -- Brazil -- References -- The British Virgin Islands -- References -- Brunei -- References -- Bulgaria -- References -- Burkina Faso -- References -- Burundi -- References -- Cambodia -- References -- Cameroon -- References -- Canada -- References -- The Canary Islands -- References -- Cape Verde -- References -- The Cayman Islands -- References -- Central African Republic -- References -- Chad --

References -- Chile -- References -- China -- References -- Colombia
-- References -- The Comoros and Mayotte -- References -- Congo --
References -- The Cook Islands -- References -- Costa Rica --
References -- Croatia -- References -- Cuba -- References -- Cyprus
-- References.

The Czech Republic -- References -- The Democratic Republic of
Congo -- References -- Denmark -- References -- Djibouti --
References -- Dominica -- References -- The Dominican Republic --
References -- Ecuador -- References -- Egypt -- References -- El
Salvador -- References -- Equatorial Guinea -- References -- Eritrea --
References -- Estonia -- References -- Eswatini -- References --
Ethiopia -- References -- The Falkland Islands -- References -- Fiji --
References -- Finland -- References -- France -- References -- French
Guiana -- References -- French Polynesia -- References -- Gabon --
References -- Gambia -- References -- Georgia -- References --
Germany -- References -- Ghana -- References -- Gibraltar --
References -- Greece -- References -- Greenland -- References --
Grenada -- References -- Guadeloupe -- References -- Guam --
References -- Guatemala -- References -- Guinea -- References --
Guinea Bissau -- References -- Guyana -- References -- Haiti --
References -- Honduras -- References -- Hong Kong -- References --
Hungary -- References -- Iceland -- References -- India -- References
-- Indonesia -- References -- Iran -- References -- Iraq -- References
-- Ireland -- References -- Israel -- References -- Italy -- References
-- Ivory Coast -- References -- Jamaica -- References -- Japan --
References -- Jordan -- References -- Kazakhstan -- References --
Kenya -- References -- Kiribati -- References -- Kosovo -- References
-- Kuwait -- References -- Kyrgyzstan -- References -- Laos --
References -- Latvia -- References -- Lebanon -- References --
Lesotho -- References -- Liberia -- References -- Libya -- References
-- Liechtenstein -- References -- Lithuania -- References --
Luxembourg -- References -- Macao -- References -- Madagascar --
References -- Malawi -- References -- Malaysia -- References -- The
Maldives -- References -- Mali.

References -- Malta -- References -- The Marshall Islands --
References -- Martinique -- References -- Mauritania -- References --
Mauritius -- References -- Mexico -- References -- Micronesia --
References -- Moldova -- References -- Monaco -- References --
Mongolia -- References -- Montenegro -- References -- Montserrat --
References -- Morocco -- References -- Mozambique -- References --
Myanmar -- References -- Namibia -- References -- Nauru -- Nepal
-- References -- The Netherlands -- References -- New Caledonia --
References -- New Zealand -- References -- Nicaragua -- References
-- Niger -- References -- Nigeria -- References -- Niue -- References
-- North Macedonia -- References -- Northern Ireland -- References
-- The Northern Marianas -- References -- Norway -- References --
Oman -- References -- Pakistan -- References -- Palau -- References
-- Panama -- References -- Papua New Guinea -- References --
Paraguay -- References -- North Korea -- References -- Peru --
References -- The Philippines -- References -- Pitcairn Island --
Poland -- References -- Portugal -- References -- Puerto Rico --
References -- Qatar -- References -- South Korea -- References --
Reunion -- References -- Romania -- References -- The Russian
Federation -- References -- Rwanda -- References -- Samoa --
References -- San Marino -- References -- Sao Tome and Principe --
References -- Saudi Arabia -- References -- Scotland -- References --
Senegal -- References -- Serbia -- References -- The Seychelles --
References -- Sierra Leone -- References -- Singapore -- References

-- Slovakia -- References -- Slovenia -- References -- The Solomon Islands -- References -- Somalia -- References -- South Africa -- References -- South Sudan -- References -- Spain -- References -- Sri Lanka -- References -- St. Helena -- References -- Saint Kitts and Nevis -- References.
Saint Lucia -- References -- Saint Vincent and The Grenadines -- References -- Sudan -- References -- Suriname -- References -- Sweden -- References -- Switzerland -- References -- Syria -- References -- Taiwan -- References -- Tajikistan -- References -- Tanzania -- References -- Thailand -- References -- Timor-Leste -- References -- Togo -- References -- Tokelau -- Tonga -- References -- Trinidad and Tobago -- References -- Tunisia -- References -- Turkey -- References -- Turkmenistan -- References -- The Turks and Caicos Islands -- References -- Tuvalu -- Uganda -- References -- Ukraine -- References -- The United Arab Emirates -- References -- The United Kingdom -- References -- The United States -- References -- Uruguay -- References -- Uzbekistan -- References -- Vanuatu -- References -- Venezuela -- References -- Vietnam -- References -- The U.S. Virgin Islands -- References -- Wallis and Futuna Islands -- References -- Western Sahara -- References -- Yemen -- References -- Zambia -- References -- Zimbabwe -- References -- Vaccines & Immunoglobulins -- Bamlanivimab -- Mechanism of Action -- Typical Adult Dosage -- Typical Pediatric Dosage -- Subsequent booster -- Toxic Effects for Bamlanivimab (2 listed) -- Contraindications for Bamlanivimab (0 listed) -- Trade names of Bamlanivimab (3 listed) -- Bebtelovimab -- Mechanism of Action -- Typical Adult Dosage -- Typical Pediatric Dosage -- Subsequent booster -- Toxic Effects for Bebtelovimab (5 listed) -- Contraindications for Bebtelovimab (0 listed) -- Trade names of Bebtelovimab (1 listed) -- Bimervax -- Mechanism of Action -- Typical Adult Dosage -- Typical Pediatric Dosage -- Subsequent booster -- Toxic Effects for Bimervax (6 listed) -- Contraindications for Bimervax (2 listed) -- Trade names of Bimervax (1 listed) -- Casirivimab / Imdevimab -- Mechanism of Action. Typical Adult Dosage -- Typical Pediatric Dosage -- Subsequent booster -- Toxic Effects for Casirivimab / Imdevimab (6 listed) -- Contraindications for Casirivimab / Imdevimab (1 listed) -- Trade names of Casirivimab / Imdevimab (2 listed) -- COVID-19 - inactivated vaccine -- Mechanism of Action -- Typical Adult Dosage -- Typical Pediatric Dosage -- Subsequent booster -- Toxic Effects for COVID-19 - inactivated vaccine (13 listed) -- Contraindications for COVID-19 - inactivated vaccine (2 listed) -- Trade names of COVID-19 - inactivated vaccine (14 listed) -- COVID-19 - mRNA vaccine -- Mechanism of Action -- Typical Adult Dosage -- Typical Pediatric Dosage -- Subsequent booster -- Toxic Effects for COVID-19 - mRNA vaccine (16 listed) -- Contraindications for COVID-19 - mRNA vaccine (1 listed) -- Trade names of COVID-19 - mRNA vaccine (8 listed) -- COVID-19 - recombinant nanoparticle vaccine -- Mechanism of Action -- Typical Adult Dosage -- Typical Pediatric Dosage -- Subsequent booster -- Toxic Effects for COVID-19 - recombinant nanoparticle vaccine (7 listed) -- Contraindications for COVID-19 - recombinant nanoparticle vaccine (2 listed) -- Trade names of COVID-19 - recombinant nanoparticle vaccine (10 listed) -- COVID-19 - viral vector vaccine -- Mechanism of Action -- Typical Adult Dosage -- Typical Pediatric Dosage -- Subsequent booster -- Toxic Effects for COVID-19 - viral vector vaccine (11 listed) -- Contraindications for COVID-19 - viral vector vaccine (1 listed) -- Trade names of COVID-19 - viral vector vaccine (14 listed) -- Pemivibart -- Mechanism of Action -- Typical

Adult Dosage -- Typical Pediatric Dosage -- Subsequent booster --
Toxic Effects for Pemivibart (2 listed) -- Contraindications for
Pemivibart (1 listed) -- Trade names of Pemivibart (1 listed) --
Regdanvimab -- Mechanism of Action -- Typical Adult Dosage.
Typical Pediatric Dosage.
